Yesterday, July 25, 2016, 24 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $14,045.55 to $139,852,750.00.

Highlighted Stocks Traded by Insiders:

Skullcandy (SKUL) - FREE Research Report

Ptarmagin, Llc, who is 10% Owner at Skullcandy, sold 37,500 shares at $5.96 on July 25, 2016. Following this transaction, the 10% Owner owned 3.4 million shares meaning that the stake was reduced by 1.1% with the 37,500-share transaction.

The shares most recently traded at $6.09, up $0.13, or 2.13% since the insider transaction. Historical insider transactions for Skullcandy go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 137,500
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 487,500
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 1.0 million

The average volume for Skullcandy has been 588,700 shares per day over the past 30 days. Skullcandy has a market cap of $170.9 million and is part of the consumer goods sector and consumer durables industry. Shares are up 28.33% year-to-date as of the close of trading on Monday.

Skullcandy Inc. designs, markets, and distributes audio and gaming products under the Skullcandy and Astro Gaming brands in the United States and internationally. The company has a P/E ratio of 0.0. Currently, there is 1 analyst who rates Skullcandy a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKUL - FREE

TheStreet Quant Ratings rates Skullcandy as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Skullcandy Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Electronic Arts (EA) - FREE Research Report

Jorgensen Blake J, who is EVP & Chief Financial Officer at Electronic Arts, sold 10,100 shares at $76.44 on July 25, 2016. Following this transaction, the EVP & Chief Financial Officer owned 109,700 shares meaning that the stake was reduced by 8.43% with the 10,100-share transaction.

The shares most recently traded at $76.96, up $0.52, or 0.68% since the insider transaction. Historical insider transactions for Electronic Arts go as follows:

  • 4-Week # shares sold: 51,403
  • 12-Week # shares sold: 327,748
  • 24-Week # shares sold: 407,648

The average volume for Electronic Arts has been 3.7 million shares per day over the past 30 days. Electronic Arts has a market cap of $23.0 billion and is part of the technology sector and computer software & services industry. Shares are up 11.9% year-to-date as of the close of trading on Monday.

Electronic Arts Inc. develops, markets, publishes, and distributes games, content, and services for consoles, personal computers, mobile phones, and tablets worldwide. The company has a P/E ratio of 28.4. Currently, there are 13 analysts who rate Electronic Arts a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EA - FREE

TheStreet Quant Ratings rates Electronic Arts as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Electronic Arts Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ARIAD Pharmaceuticals (ARIA) - FREE Research Report

Clackson Timothy P, who is President, R&D, CSO at ARIAD Pharmaceuticals, sold 18,286 shares at $8.11 on July 25, 2016. Following this transaction, the President, R&D, CSO owned 248,208 shares meaning that the stake was reduced by 6.86% with the 18,286-share transaction.

The shares most recently traded at $8.05, down $0.06, or 0.7% since the insider transaction. Historical insider transactions for ARIAD Pharmaceuticals go as follows:

  • 4-Week # shares bought: 26,990
  • 4-Week # shares sold: 23,999
  • 12-Week # shares bought: 26,990
  • 12-Week # shares sold: 41,761
  • 24-Week # shares bought: 26,990
  • 24-Week # shares sold: 102,426

The average volume for ARIAD Pharmaceuticals has been 4.4 million shares per day over the past 30 days. ARIAD Pharmaceuticals has a market cap of $1.6 billion and is part of the health care sector and drugs industry. Shares are up 31.2% year-to-date as of the close of trading on Monday.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. Currently, there are 3 analysts who rate ARIAD Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARIA - FREE

TheStreet Quant Ratings rates ARIAD Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full ARIAD Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.